Thiogenesis Announces Results from Annual and Special Meeting of Shareholders
San Diego, California--(Newsfile Corp. - September 26, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that shareholders have approved all matters put forward at its Annual and Special Meeting ("ASM") held on September 19th, 2022. All five members of the Company's board of directors, Dr. Patrice Rioux, Dr. Christopher Starr, Kim Tsuchimoto, Hogan Mullally and Brook Riggins, named as nominees in the Company's management information...
2022-09-26 9:30 AM EDT
Thiogenesis Announces the Formation of its Scientific Advisory Board
San Diego, California--(Newsfile Corp. - August 30, 2022) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases today announced the formation of its Scientific Advisory Board ("SAB"). The SAB members are acclaimed leaders in their fields and will provide strategic guidance utilizing their vast experience to support the successful clinical and commercial...
2022-08-30 9:00 AM EDT
Thiogenesis Announces Positive Results from Phase 1 Dose-Escalation Study of its Lead Compound TTI-0102
San Diego, California--(Newsfile Corp. - May 18, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for serious pediatric diseases, today announces positive results from its Phase 1 clinical study of oral TTI-0102 in healthy volunteers in Australia. The Phase 1, "O
2022-05-18 9:00 AM EDT
CORRECTION FROM SOURCE: Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it closed its previously announced Qualifying Transaction (the "QT") as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Thiogenesis Therapeutics, Inc. ("TTI-US") (see the Company's press releases dated March 12, 2021, March 23, 2021, J
2022-04-05 11:19 PM EDT
Thiogenesis Therapeutics, Corp. Announces Closing of Qualifying Transaction
Toronto, Ontario--(Newsfile Corp. - April 5, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("TTI" or the "Company") (formerly Rozdil Capital Corporation) is pleased to announce that on March 31, 2022, it closed its previously announced Qualifying Transaction (the "QT") as defined by Policy 2.4 of the TSX Venture Exchange (the "Exchange") with Thiogenesis Therapeutics, Inc. ("TTI-US") (see the Company's press releases dated March 12, 2021, March 23, 2021, July 27, 2021 and March 21,...
2022-04-05 4:57 PM EDT
Rozdil Capital Corporation Completes Initial Public Offering; Common Shares Commence Trading
Toronto, Ontario--(Newsfile Corp. - July 16, 2019) - Rozdil Capital Corporation (TSXV: ROZ.P) (the "Corporation") is pleased to announce that it has successfully completed its initial public offering of 2,150,000 common shares (the "Common Shares") at $0.10 per share for gross proceeds of $215,000 (the "Offering"). As a result of this issuance, the Corporation has 4,500,000 Common Shares issued and outstanding, of which 2,350,000 Common Shares are subject to escrow restrictions as disclosed...
2019-07-16 9:00 AM EDT